Recipharm AB (publ) agreed to acquire Arranta Bio Holdings, LLC from Ampersand Capital Partners and others on February 21, 2022. The acquisition is subject to customary regulatory filings and is expected to be completed around the end of March, 2022. Centerview Partners UK LLP acted as exclusive financial adviser, and Aneeq K. Durrani, Leo M. Greenberg, Roger Johnson; Michael S. Amalfe, Niklas Ahlklo, David M. Towarnicky, James L. Walker, Raisa Masud, Lawrence Ho and Katie M. Sullivan of Kirkland & Ellis LLP served as counsel to Recipharm on the transaction. Morgan Stanley & Co. LLC acted as exclusive financial adviser and Goodwin Procter LLP served as counsel to Arranta Bio.

Recipharm AB (publ) completed the acquisition of Arranta Bio Holdings, LLC from Ampersand Capital Partners and others on April 11, 2022.